Journal article icon

Journal article

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.

Abstract:

Patients with impaired glucose tolerance (IGT) have increased risk for developing type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Lifestyle modification and medication can prevent or delay progression to diabetes (PD), but whether such interventions also reduce the risk of CVD has not been rigorously tested. The Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial is a multinational, randomized, double-blind, 2 x 2 factorial trial in su...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1016/j.ahj.2008.05.017

Authors


Journal:
American heart journal More from this journal
Volume:
156
Issue:
4
Pages:
623-632
Publication date:
2008-10-01
DOI:
EISSN:
1097-6744
ISSN:
0002-8703

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP